LENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at TD Cowen

Stock analysts at TD Cowen assumed coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $60.00 price target on the stock. TD Cowen’s price objective suggests a potential upside of 154.35% from the stock’s previous close.

LENZ Therapeutics Trading Down 7.3 %

LENZ stock opened at $23.59 on Tuesday. LENZ Therapeutics has a 1-year low of $14.42 and a 1-year high of $38.93. The firm has a fifty day moving average price of $24.16 and a two-hundred day moving average price of $27.02.

Hedge Funds Weigh In On LENZ Therapeutics

A number of large investors have recently bought and sold shares of LENZ. Paradigm Biocapital Advisors LP acquired a new stake in shares of LENZ Therapeutics during the 4th quarter worth approximately $22,243,000. Price T Rowe Associates Inc. MD grew its stake in LENZ Therapeutics by 83.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company’s stock worth $23,760,000 after buying an additional 374,326 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new stake in LENZ Therapeutics in the third quarter worth $3,308,000. Charles Schwab Investment Management Inc. increased its position in LENZ Therapeutics by 197.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company’s stock worth $2,929,000 after buying an additional 81,901 shares during the period. Finally, Vanguard Group Inc. lifted its stake in LENZ Therapeutics by 5.3% in the fourth quarter. Vanguard Group Inc. now owns 1,178,447 shares of the company’s stock valued at $34,022,000 after buying an additional 59,630 shares during the last quarter. Institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.